Premium
Effect of antidepressant treatment on plasma levels of neuroinflammation‐associated molecules in patients with somatic symptom disorder with predominant pain around the orofacial region
Author(s) -
Miyauchi Tomoya,
Tokura Tatsuya,
Kimura Hiroyuki,
Ito Mikiko,
Umemura Eri,
Sato Boku Aiji,
Nagashima Wataru,
Tonoike Takashi,
Yamamoto Yasuko,
Saito Kuniaki,
Kurita Kenichi,
Ozaki Norio
Publication year - 2019
Publication title -
human psychopharmacology: clinical and experimental
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.461
H-Index - 78
eISSN - 1099-1077
pISSN - 0885-6222
DOI - 10.1002/hup.2698
Subject(s) - neuroinflammation , pathophysiology , medicine , burning mouth syndrome , orofacial pain , endocrinology , inflammation , surgery
Objective Burning mouth syndrome (BMS) and atypical odontalgia (AO) are examples of somatic symptom disorders with predominant pain around the orofacial region. Neuroinflammation is thought to play a role in the mechanisms, but few studies have been conducted. We aimed to better understand the role of neuroinflammation in the pathophysiology and treatment of BMS/AO. Methods Plasma levels of 28 neuroinflammation‐related molecules were determined in 44 controls and 48 BMS/AO patients both pretreatment and 12‐week post‐treatment with duloxetine. Results Baseline plasma levels of interleukin (IL)‐1β ( p < .0001), IL‐1 receptor antagonist ( p < .001), IL‐6 ( p < .0001), macrophage inflammatory protein‐1β ( p < .0001), and platelet‐derived growth factor‐bb (.04) were significantly higher in patients than in controls. Plasma levels of granulocyte macrophage colony stimulating factor were significantly higher in patients than in controls ( p < .001) and decreased with treatment (.009). Plasma levels of eotaxin, monocyte chemoattractant protein‐1, and vascular endothelial growth factor decreased significantly with treatment ( p < .001, .022, and .029, respectively). Conclusions Inflammatory mechanisms may be involved in the pathophysiology and/or treatment response of somatic symptom disorders with predominant pain around the orofacial region.